131 related articles for article (PubMed ID: 18039573)
1. Antitumor effects of curcumin and structurally beta-diketone modified analogs on multidrug resistant cancer cells.
Simoni D; Rizzi M; Rondanin R; Baruchello R; Marchetti P; Invidiata FP; Labbozzetta M; Poma P; Carina V; Notarbartolo M; Alaimo A; D'Alessandro N
Bioorg Med Chem Lett; 2008 Jan; 18(2):845-9. PubMed ID: 18039573
[TBL] [Abstract][Full Text] [Related]
2. Curcumin as a possible lead compound against hormone-independent, multidrug-resistant breast cancer.
Labbozzetta M; Notarbartolo M; Poma P; Maurici A; Inguglia L; Marchetti P; Rizzi M; Baruchello R; Simoni D; D'Alessandro N
Ann N Y Acad Sci; 2009 Feb; 1155():278-83. PubMed ID: 19250217
[TBL] [Abstract][Full Text] [Related]
3. The antitumor activities of curcumin and of its isoxazole analogue are not affected by multiple gene expression changes in an MDR model of the MCF-7 breast cancer cell line: analysis of the possible molecular basis.
Poma P; Notarbartolo M; Labbozzetta M; Maurici A; Carina V; Alaimo A; Rizzi M; Simoni D; D'Alessandro N
Int J Mol Med; 2007 Sep; 20(3):329-35. PubMed ID: 17671737
[TBL] [Abstract][Full Text] [Related]
4. Lack of nucleophilic addition in the isoxazole and pyrazole diketone modified analogs of curcumin; implications for their antitumor and chemosensitizing activities.
Labbozzetta M; Baruchello R; Marchetti P; Gueli MC; Poma P; Notarbartolo M; Simoni D; D'Alessandro N
Chem Biol Interact; 2009 Sep; 181(1):29-36. PubMed ID: 19539615
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents.
Adams BK; Ferstl EM; Davis MC; Herold M; Kurtkaya S; Camalier RF; Hollingshead MG; Kaur G; Sausville EA; Rickles FR; Snyder JP; Liotta DC; Shoji M
Bioorg Med Chem; 2004 Jul; 12(14):3871-83. PubMed ID: 15210154
[TBL] [Abstract][Full Text] [Related]
6. Antitumor agents 247. New 4-ethoxycarbonylethyl curcumin analogs as potential antiandrogenic agents.
Lin L; Shi Q; Su CY; Shih CC; Lee KH
Bioorg Med Chem; 2006 Apr; 14(8):2527-34. PubMed ID: 16427289
[TBL] [Abstract][Full Text] [Related]
7. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB in breast cancer cells and potentiates the growth inhibitory effect of paclitaxel in a breast cancer nude mice model.
Kang HJ; Lee SH; Price JE; Kim LS
Breast J; 2009; 15(3):223-9. PubMed ID: 19645775
[TBL] [Abstract][Full Text] [Related]
8. Significance of autologous interleukin-6 production in the HA22T/VGH cell model of hepatocellular carcinoma.
Labbozzetta M; Notarbartolo M; Poma P; Giannitrapani L; Cervello M; Montalto G; D'Alessandro N
Ann N Y Acad Sci; 2006 Nov; 1089():268-75. PubMed ID: 17261774
[TBL] [Abstract][Full Text] [Related]
9. Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells.
Ganta S; Amiji M
Mol Pharm; 2009; 6(3):928-39. PubMed ID: 19278222
[TBL] [Abstract][Full Text] [Related]
10. Antitumor agents 243. Syntheses and cytotoxicity of desmosdumotin C derivatives.
Nakagawa-Goto K; Wu JH; Bastow KF; Wu CC; Lee KH
Bioorg Med Chem; 2005 Mar; 13(6):2325-30. PubMed ID: 15727881
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationship studies of curcumin analogues.
Fuchs JR; Pandit B; Bhasin D; Etter JP; Regan N; Abdelhamid D; Li C; Lin J; Li PK
Bioorg Med Chem Lett; 2009 Apr; 19(7):2065-9. PubMed ID: 19249204
[TBL] [Abstract][Full Text] [Related]
12. Curcumin promotes apoptosis in A549/DDP multidrug-resistant human lung adenocarcinoma cells through an miRNA signaling pathway.
Zhang J; Zhang T; Ti X; Shi J; Wu C; Ren X; Yin H
Biochem Biophys Res Commun; 2010 Aug; 399(1):1-6. PubMed ID: 20627087
[TBL] [Abstract][Full Text] [Related]
13. Imatinib resistance in multidrug-resistant K562 human leukemic cells.
Assef Y; Rubio F; Coló G; del Mónaco S; Costas MA; Kotsias BA
Leuk Res; 2009 May; 33(5):710-6. PubMed ID: 18977528
[TBL] [Abstract][Full Text] [Related]
14. Novel curcumin analogs targeting TNF-induced NF-kappaB activation and proliferation in human leukemic KBM-5 cells.
Zambre AP; Kulkarni VM; Padhye S; Sandur SK; Aggarwal BB
Bioorg Med Chem; 2006 Nov; 14(21):7196-204. PubMed ID: 16843665
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of curcumin mimics with multidrug resistance reversal activities.
Um Y; Cho S; Woo HB; Kim YK; Kim H; Ham J; Kim SN; Ahn CM; Lee S
Bioorg Med Chem; 2008 Apr; 16(7):3608-15. PubMed ID: 18295490
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and structure-activity relationships of taxuyunnanine C derivatives as multidrug resistance modulator in MDR cancer cells.
Hasegawa T; Bai J; Dai J; Bai L; Sakai J; Nishizawa S; Bai Y; Kikuchi M; Abe M; Yamori T; Tomida A; Tsuruo T; Hirose K; Ando M
Bioorg Med Chem Lett; 2007 Jul; 17(13):3722-8. PubMed ID: 17490878
[TBL] [Abstract][Full Text] [Related]
17. Novel D: -erythro N-octanoyl sphingosine analogs as chemo- and endocrine-resistant breast cancer therapeutics.
Antoon JW; Liu J; Ponnapakkam AP; Gestaut MM; Foroozesh M; Beckman BS
Cancer Chemother Pharmacol; 2010 May; 65(6):1191-5. PubMed ID: 20155475
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial and cytotoxic activity of agelasine and agelasimine analogs.
Vik A; Hedner E; Charnock C; Tangen LW; Samuelsen Ø; Larsson R; Bohlin L; Gundersen LL
Bioorg Med Chem; 2007 Jun; 15(12):4016-37. PubMed ID: 17442577
[TBL] [Abstract][Full Text] [Related]
19. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
20. SAR studies of brasilicardin A for immunosuppressive and cytotoxic activities.
Komatsu K; Tsuda M; Tanaka Y; Mikami Y; Kobayashi J
Bioorg Med Chem; 2005 Mar; 13(5):1507-13. PubMed ID: 15698766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
